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ABSTRACT
Oralmucositis, a severe oral ulceration, is a common toxic
effect of radio- or chemoradio-therapy and a limiting factor
to using the maximum dose of radiation for effective can-
cer treatment. Among cancer patients, at least 40%and up
to 70%, of individuals treatedwith standard chemotherapy
regimens or upper-body radiation, develop oralmucositis.
To date, there is no FDA approved drug to treat oral mu-
cositis in cancer patients. The key challenges for oral
mucositis treatmentare to repair andprotectulceratedoral
mucosa without promoting cancer cell growth. Oral mu-
cositis is the result of complex,multifaceted pathobiology,
involving a series of signaling pathways and a chain of
interactions between the epithelium and submucosa.
Among those pathways and interactions, the activation of
nuclear factor-kappa B (NF-κB) is critical to the inﬂamma-
tion process of oral mucositis. We recently found that
activationofTGFβ (transforminggrowth factorβ) signaling
is associated with the development of oral mucositis.
Smad7, the negative regulator of TGFβ signaling, inhibits
both NF-κB and TGFβ activation and thus plays a pivotal
role in the prevention and treatment of oral mucositis by
attenuatinggrowth inhibition,apoptosis, and inﬂammation
while promoting epithelial migration. The major objective
of this review is to evaluate the known functionsof Smad7,
with a particular focus on its molecular mechanisms and
its function in blockingmultiple pathological processes in
oral mucositis.
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ORAL MUCOSITIS FREQUENCY
Oral mucositis, a severe oral ulceration, is a common toxic
effect of radiation for bone marrow transplant and upper body
radiotherapy or chemo-radiotherapy for all cancer types
(Sonis, 2010; Vagliano et al., 2011). Severe oral mucositis is
extremely painful and impairs food/liquid intake, and is rated
by patients as the most debilitating side effect of cancer
therapy (Bellm et al., 2000). At least 40%, and up to 70%, of
individuals treated with standard chemotherapy regimens or
upper-body radiation develop oral mucositis (Scully et al.,
2003). Among them, over 80% of oral cancer patients (the 6th
most common cancer worldwide) are treated with radiation
and at least 70% develop severe oral mucositis (Trotti et al.,
2003; Vera-Llonch et al., 2006). The use of intensity modu-
lated radiotherapy (IMRT) spares more normal tissue and
lessens chronic side effects, but does not alleviate the acute
toxicity seen in oral mucosa (Khuntia D et al., 2008) and
certain patients are at a high risk of oral mucositis regardless
of treatment regimen (Scully et al., 2006). Further, many high
risk patients experience ampliﬁed acute oral mucositis when
receiving radiotherapy combined with targeted therapies
(Sonis, 2013). In the US, there are at least one million oral
mucositis patients every year. Costs to care for oral mucositis
can be up to $6,000 per patient per chemo- or radiation cycle
for narcotic therapy, antibiotics, anemia, liquid diet, additional
ofﬁce visits, and nursing staff costs. For more severe oral
mucositis cases, when a feeding tube and additional hospi-
talization are needed, the cost of associated care can be up
to $25,000/cycle. Because there is no effective treatment,
oral mucositis lesions are often serious enough to delay,
reduce or halt cancer therapy. Palifermin, a human kerati-
nocyte growth factor (KGF) recombinant protein, is the only
FDA approved targeted therapy for preventing oral mucositis
in bone-marrow transplant patients (4% of the at-risk popu-
lation), but it has no effect on existing mucositis (Sonis,
2010). Palifermin clinical trials in head and neck cancer
patients showed only modest preventive effects on severe
oral mucositis incidence (Henke et al., 2011; Le et al., 2011).
The incidence and severity of mucositis depends on
multiple factors, including chemotherapeutic agents and
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doses, radiation regimen, patient age, gender, nutritional
status, oral microbiota, salivary secretory function, and
genetic variation (Barasch and Peterson, 2003; Sonis, 2009).
PATHOLOGICAL PROCESSES OF ORAL
MUCOSITIS
Oral mucositis is characterized by an inﬁltration of excessive
inﬂammatory cells, epithelial ablation, and ulcer develop-
ment (Scully et al., 2006; Wu et al., 2010). Oral mucositis
consists of ﬁve overlapping stages: initiation, damage
response, signal ampliﬁcation, ulceration, and healing. At the
initiation stage, radiotherapy or chemotherapy injures the
tissue through DNA strand breaks, cell death in the basal
and suprabasal layers, and halting epithelial proliferation.
Additionally, the injured tissue produces reactive oxygen
species (ROS), which in turn induce oxidative stress-asso-
ciated DNA damage. Apart from the epithelial injury, radio-
therapy and chemotherapy also exacerbate the mucosal
damage by effecting the underlying submucosa, including
endothelia, ﬁbroblasts, and leukocytes (Treister and Sonis;
Denham and Hauer-Jensen, 2002; Sonis, 2004a; Lalla and
Peterson, 2006). During the damage response stage, sub-
mucosal cells expressing early response genes, such as
c-jun, c-fos, and Erg-1, join in the intricate series of biological
cascades, and several signal transduction pathways are
activated. Among them, NF-κB is one of the most signiﬁ-
cantly activated pathways, which upregulates many genes to
elicit a wide range of tissue responses and affect the process
of oral mucositis (Sonis, 2002; Sonis, 2004a). At the sig-
naling ampliﬁcation stage, pro-inﬂammatory cytokines such
as NF-κB, tumor-necrosis factor-α (TNF-α), interleukin-1β
(IL-1β), interleukin-6 (IL-6), ceramide, and matrix metallo-
proteinases (MMPs), are overproduced. Mucosal damage
triggers the initial release of these factors, leading to the
positive feedback loop that ampliﬁes mucosal damage (So-
nis, 2002; Sonis, 2004a). At the ulceration stage, the integrity
of the epithelium disintegrates and ulceration occurs with a
massive inﬁltration of leukocytes in response to both tissue
injury and secondary microbial infection. (Treister and Sonis;
Sonis, 2004a). Subsequently, tissue begins to heal. In the
healing stage, the epithelium is re-epithelialized by migrating
keratinocytes followed by keratinocyte proliferation to restore
normal epithelial layers that are remodeled by differentiation.
Inﬂammation is reduced, and stromal ﬁbroblasts as well as
vessels are remodeled (Treister and Sonis; Sonis, 2004a).
ORAL MUCOSITIS CARE AND EXPERIMENTAL
THERAPEUTICS
Due to the complex and multifaceted pathobiology of oral
mucositis (Sonis, 2004b), diverse interventions have been
tested (Lalla et al., 2014). Based on these studies, the
Multinational Association of Supportive Care in Cancer/
National Society of Oral Oncology (MASCC/ISOO) recently
revised evidence-based clinical practice guidelines for oral
mucositis care (Table 1). In general, oral mucositis care
involves basic oral care and control of symptoms through the
use of antimicrobials, coating agents, anesthetics, and
analgesics. Oral mucositis interventions are focused on
growth factors and anti-inﬂammatory agents (Lalla et al.,
2014). Although several growth factors, such as KGF (Henke
et al., 2011; Le, 2011; Weigelt et al., 2011), epidermal growth
factor (EGF) (Epstein et al., 2000; Wu et al., 2009), and
granulocyte-colony-stimulating factor (G-CSF) (Jyung et al.,
1994; Raber-Durlacher et al., 2013) have been explored for
oral mucositis treatment, Palifermin (truncated KGF) is the
only US FDA approved drug recommended by MASCC/
ISOO for oral mucositis prevention (Spielberger et al., 2004;
Raber-Durlacher et al., 2013). The major concern when
using a growth factor to treat oral mucositis is the potential
oncogenic effect that would compromise cancer treatment.
Among studied anti-inﬂammatory agents, benzydamine is an
effective antioxidant, anti-inﬂammatory agent, and inhibitor
of leukocyte-endothelial interactions (Epstein et al., 2001),
also having analgesic, anesthetic, and antimicrobial activi-
ties (Rubenstein et al., 2004). Therefore, the MASCC/ISOO
guidelines recommend benzydamine mouthwash for the
prevention of radiation-induced mucositis in patients with
head and neck cancer receiving moderate dose radiotherapy
(Nicolatou-Galitis et al., 2013). However, not all anti-inﬂam-
matory agents are effective at alleviating oral mucositis (Lalla
et al., 2014).
In addition to therapeutic agents, laser or other light
therapy and cryotherapy have also been explored for oral
mucositis prevention. Low-level laser therapy has been
shown to have photochemical, photophysical, and photobi-
ological effects on cellular metabolism (Migliorati, 2013).
Cryotherapy causes vasoconstriction and decreases blood
ﬂow to the oral cavity, reducing exposure of the buccal
mucosa to chemotherapy (Sorensen et al., 2008). However,
its usefulness is limited to only a few chemotherapeutics with
short half-lives (Peterson et al., 2013). Further, a large
number of natural agents have been explored for oral mu-
cositis treatment (Lalla et al., 2014). Among them, zinc, an
essential trace element for some tissue repair processes
with antioxidant effects (Yarom et al., 2013), is the only one
suggested by the MASCC/ISOO for oral mucositis preven-
tion (Lalla et al., 2014). Overall, among the MASCC/ISOO
recommended/suggested therapies, each primarily targets
one of the pathological processes of oral mucositis and thus
is only moderately effective. This situation highlights the
need for a new therapeutic strategy.
ROLE OF TGFβ SIGNALING IN INFLAMMATION AND
ORAL MUCOSITIS
TGFβ has three isoforms and TGFβ1 is the predominant
form in keratinocytes (Pittelkow et al., 1988). TGFβ signals
through type I and type II receptors that have serine/
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threonine kinase activities and downstream Smad proteins,
speciﬁcally Smad2 and Smad3 (Fig. 1) (Massague and
Gomis, 2006). After ligand binding, the type I receptor
phosphorylates Smad2 and Smad3, which then bind to
Smad4, forming a trimeric complex that translocates from the
cytoplasm into the nucleus. The trimeric Smad complex
binds to Smad binding elements (SBEs) to regulate gene
expression (Feng and Derynck, 2005; Groneberg et al.,
2004).
TGFβ1 was initially identiﬁed as an immunosuppressive,
anti-inﬂammatory molecule (Shull et al., 1992; Kulkarni et al.,
1993). TGFβ1-deﬁcient mice exhibit inﬂammation in multiple
organs, succumbing to multifocal inﬂammation and autoim-
mune disorders in the internal organs (Shull et al., 1992;
Kulkarni et al., 1993). However, TGFβ1 also has a pro-
inﬂammatory effect. Levels of TGFβ1 increase rapidly fol-
lowing injury due to secretion by keratinocytes, platelets, and
macrophages (Singer and Clark, 1999), and increased levels
of TGFβ1 rapidly recruit leukocytes to accumulate at the
injury site. Inﬁltrated leukocytes secrete chemokines and
inﬂammatory cytokines stimulating the inﬂammatory
response (Wang et al., 2006). The pro-inﬂammatory effect of
TGFβ1 is further substantiated in K5.TGFβ1 transgenic mice
with latent human TGFβ1 overexpression in the skin and oral
mucosa (Li et al., 2004a; Lu et al., 2004), where severe
inﬂammation is observed.
Our recent study identiﬁed increased TGFβ protein and
signaling activities in both human oral mucositis lesions and
radiation-induced oral mucositis in mice (Han et al., 2013).
Because TGFβ is a potent epithelial cell growth inhibitor,
activated TGFβ induces growth arrest of irradiated epithelial
cells. Arresting these cells could allow them to repair dam-
aged DNA, but severe growth arrest also contributes to the
thinning of epithelial layers and progression to an ulcer.
TABLE 1. MASCC/ISOO clinical practice guidelines for care of patients with oral mucositis
Intervention Purpose Treatment category/patient population Guideline
Basic oral care
Oral care Prevention All patients Suggested
Chlorhexidine mouthwash Prevention Radiotherapy for HNC Suggested
Cytokines and growth factors
Palifermin (truncated KGF) Prevention High-dose chemotherapy and total body
irradiation followed by autologous stem cell
transplantation for a hematological malignancy
Recommended
Anti-inﬂammatory agents
Benzydamine mouthwash Prevention Moderate dose radiation therapy (up to 50 Gy),
without concomitant chemotherapy in patients
with HNC
Recommended
Antimicrobials, coating agents, anesthetics, and analgesics
Patient-controlled analgesia with morphine Treat pain HSCT Recommended
Transdermal fentanyl Treat pain Conventional or high-dose chemotherapy, with
or without total body irradiation
Suggested
2% morphine mouthwash Treat pain Radiotherapy for HNC Suggested
0.5% doxepin mouthwash Treat pain Radiotherapy for HNC Suggested
Device directed therapies
Low-level laser (wavelength at 650 nm) Prevention HSCT conditioned with high-dose
chemotherapy, with or without total body
irradiation
Recommended
Low-level laser (wavelength ∼632.8 nm) Prevention H&N RT without concomitant chemotherapy Suggested
Cryotherapy Prevention Bolus 5-ﬂuorouracil chemotherapy
High-dose melphalan, with or without total body
irradiation, as conditioning for HSCT
Recommended
Suggested
Natural and miscellaneous agents
Zinc supplements Prevention Radiotherapy or chemoradiotherapy for oral
cancer
Suggested
Abbreviations: Gy, grays; HSCT, hematopoietic stem cell transplantation; MASCC/ISOO, Multinational Association of Supportive Care in
Cancer and International Society of Oral Oncology; KGF, Keratinocyte growth factor; head and neck radiation therapy (H&N RT) head and neck
cancer (HNC).
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Additionally, TGFβ induces apoptosis, potentially contribut-
ing greatly to the massive cell death found in oral mucositis.
Further, our previous study showed that TGFβ1 activates
NF-κB (Li et al., 2004b) and elicits severe inﬂammation in
oral mucosa (Lu et al., 2004). Excessive inﬂammation in oral
mucositis could therefore be largely due to TGFβ overex-
pression. Our study suggests that TGFβ contributes to
multiple pathological processes responsible for oral muco-
sitis development. Further, our previous study has shown
that excessive and prolonged TGFβ1 expression in kerati-
nocytes resulted in delayed wound healing (Wang et al.,
2006). Therefore, increased TGFβ in oral mucositis would
also delay its healing.
SMAD7: A TGFβ SIGNALING ANTAGONIST AND
CROSS-TALK MEDIATOR OF MULTIPLE PATHWAYS
IN DISEASES
Smad7, a nuclear protein, was initially identiﬁed to block
TGFβ signaling through translocation to the cytoplasm to
block phosphorylation of Smad2/3 (Hayashi et al., 1997;
Nakao et al., 1997; Nakao et al.,2002). Later, Smad7 was
found to recruit E3 ubiquitin ligases (Smurf1 and Smurf2) to
degrade TGFβRI and Smad2/3 (Kavsak et al., 2000; Lin
et al., 2000; Ebisawa et al., 2001). Smad7 also binds to DNA
through its MH2 domain to regulate transcription (Yan and
Chen, 2011).
Because TGFβ is a potent growth inhibitor for epithelial
cells and induces apoptosis in many cell types, Smad7
promotes cell proliferation and survival once it reaches a
level sufﬁcient to block TGFβ signaling (He et al., 2002;
Han et al., 2011). These functions of Smad7 contrib-
ute greatly to its role in promoting wound healing after
injuries, when cell proliferation is required (Mallawaarach-
chi et al., 2005; Saika et al., 2005; Han et al., 2011).
Additionally, Smad7 promotes cell migration, required for
normal wound healing, through interactions with other
pathways. Speciﬁcally, Smad7 promotes the MAPK3-p38
complex formation to activate JNK/p38 (Edlund et al.,
2003), activates Erk (Han et al., 2011), and recruits ade-

















Figure 1. TGFβ signaling components. TGFβ signals through type I and type II receptors when TGFβ ligand binds to the type II
receptor. The serine/threonine kinase of the type I receptor phosphorylates Smad2 and Smad3, which then bind to Smad4, forming a
trimeric complex that translocates from the cytoplasm into the nucleus. The trimeric Smad complex binds to Smad binding elements
(SBEs) to regulate gene expression. Smad7 is a nuclear protein. It competes with signaling Smads on SBEs, and translocates to the
cytoplasm to block phosphorylation of Smad2/3 or induce degradation of TGFβRI and Smad2/3.
The role of Smad7 in oral mucositis REVIEW









Smad7 is expressed at exceedingly low levels in normal
keratinocytes (He et al., 2001), but is often overexpressed
under pathological conditions (He et al., 2002; Han et al.,
2011). Inﬂammatory diseases frequently show elevated
TGFβ-induced levels of Smad7 expression. Because TGFβ
in the skin and oral mucosa primarily functions as a pro-
inﬂammatory cytokine, the anti-TGFβ effect of Smad7 makes
it act as an anti-inﬂammatory molecule. Further, Smad7
directly antagonizes NF-κB, the major inﬂammation pathway.
Smad7 overexpression up-regulates IκBα expression, an
NF-κB inhibitor (Wang et al., 2005). Smad7 also disrupts the
formation of the protein complex TRAF2/TAK1/TAB2/TAB3
(TNF-receptor associated factor 2/TGFβ-activated kinase
1/TAK-binding protein 2/3), which is essential for activation of
the inﬂammation cascade (Hong et al., 2007). Therefore, the
anti-TGFβ and anti-NF-κB activities of Smad7 make it one of
the most potent anti-inﬂammatory molecules in stratiﬁed
epithelial tissues. Similarly, Smad7 knockout mice devel-
oped kidney inﬂammation (Chung et al., 2009; Chen et al.,
2011). In contrast, because TGFβ is a potent immune sup-
pressant in the gut, high levels of Smad7 expression in the
gut cause inﬂammatory bowel disease (IBD) due to the loss
of TGFβ responsiveness (Monteleone et al., 2004).
With respect to the role of Smad7 in tumorigenesis,
because TGFβ is a potent growth inhibitor and apoptosis
inducer, the anti-TGFβ effect of Smad7 is suspected to
promote tumor growth and survival. In support of this notion,
Smad7 overexpression is associated with poor prognosis in
colorectal cancer (Boulay et al., 2001). In experimental
models, overexpression of Smad7 can promote malignant
transformation and tumorigenicity in the pancreas, gastric,
lung, skin, and colon (Kim et al., 2004; Kleeff et al., 1999; Liu
et al., 2003; Halder et al., 2005; Luo et al., 2010). In contrast,
Smad7 has been shown to inhibit cancer progression and
metastasis in many tumor types in experimental models,
including melanoma, breast cancer colorectal cancer, head
and neck and liver cancers in vitro and in vivo (Azuma et al.,
2005; Javelaud et al., 2005; Leivonen et al., 2006; Rizzo
et al., 2011; Wang et al., 2013). Smad7’s anti-inﬂammatory
effect in certain tissues and induction of apoptosis in certain
cancer types (Wang et al., 2013) could contribute to its
tumor-suppressive effect. Additionally, because TGFβ indu-
ces formation of cancer-associated ﬁbroblasts (CAFs) to
promote cancer progression, it is not surprising that Smad7
can block this process (Li et al., 2013). Interestingly, a study
demonstrated that while Smad7 overexpression in T cells
increases colitis severity, it decreases colitis-associated
cancer (Rizzo et al., 2011). Therefore, the enhanced immune
response could also attack tumor cells, a principle for
immunotherapy in cancer.
The tissue/context-speciﬁc effects of Smad7 partially
explain the dual roles of Smad7 in cancer. Another expla-
nation could be dose-dependent effects of Smad7. For
instance, while high levels of Smad7 overexpression driven
by adenoviral transduction cause skin tumor progression in
immune compromised recipient mice (Liu et al., 2003), we
have not observed spontaneous tumor formation in K5.
Smad7 transgenic mice that express Smad7 at a modest
level, even though this level of Smad7 is sufﬁcient to block
Wnt signaling (Han, et al., 2006).
SMAD7: EFFECTS ON PREVENTION AND
TREATMENT OF ORAL MUCOSITIS
We utilized K5.Smad7 mice that express a Smad7 transgene
in oral epithelia under the control of a keratin 5 promoter, as
an animal model, to study their susceptibility to radiation-
induced oral mucositis. We found that these mice are
remarkably resistant to radiotherapy-induced oral mucositis.
This prompted us to seek a pharmacological approach to
deliver Smad7 protein into the oral cavity. Exogenous
Smad7 has to be delivered inside cells to its natural cellular
location, the nucleus. To this end, we developed a recom-
binant human Smad7 protein with an N-terminal Tat tag (Tat-
Smad7), permitting the proteins to rapidly permeate the cell
membrane and enter into the nucleus (Han et al., 2013). To
test the efﬁcacy of Tat-Smad7 in oral mucositis prevention,
we exposed mice to fractionated cranial radiation and topi-
cally applied Tat-Smad7 to the oral cavity daily starting 24 h
before irradiation through day 8 after initiation of irradiation
and observed the treated tissues on day 9. We found Tat-
Smad7 treatment signiﬁcantlly reduced ulcer incidence and
sizes. Next, we tested if Tat-Smad7 can be used to treat
existing oral mucositis. We began topical Tat-Smad7 appli-
cation 6 days after irradiation, (when mucosal damage was
obvious) applying daily to day 9 and observed the treated
tissues on day 10. Tat-Smad7 treated mice show acceler-
ated healing compared to the control group. Our studies
show that the preventive and therapeutic effects of Smad7
are due to blocking multiple pathological processes of oral
mucositis as discussed below.
Anti-inﬂammatory effects of Smad7
We found that both K5.Smad7 mice and Tat-Smad7 trea-
ted mouse oral mucosa have less inﬂammation than control
mice during radiation-induced oral mucositis. In these tis-
sues, pSmad2, a surrogate marker for TGFβ activation, and
nuclear NF-κB p50, a surrogate marker for NF-κB activation,
were both reduced by Smad7 (Han et al., 2013). Because
excessive inﬂammation and upregulation of pro-inﬂamma-
tory cytokines are early stage insults, the antagonistic effect
of Smad7 on both TGFβ and NF-κB signaling substantially
contributes to reduced mucositis formation when Smad7 is
used as a therapeutic. Because inﬂammation further exac-
erbates radiation-induced tissue damage (Sonis, 2004b),
reducing inﬂammation in pre-exisiting lesions provides a
beneﬁcial microenvironment for oral mucositis healing.
These data indicate Smad7 is a more efﬁcient anti-inﬂam-
matory molecule than other pathway inhibitors that target
REVIEW Li Bian et al.









only the NF-κB pathway or the TGFβ pathway (Han et al.,
2011; Han et al., 2013).
Role of Smad7 in proliferation and apoptosis
of epithelial cells
In previous studies, we found that Smad7 increases prolif-
eration but reduces apoptosis in stratiﬁed epithelia (He et al.,
2002). Overexpression of Smad7 can accelerate epithelial
cell proliferation and decrease levels of apoptosis, promoting
wound healing by blocking TGFβ induced growth inhibition
and apoptosis (Han et al., 2011; Han et al., 2013). In oral
mucositis, epithelial proliferation is nearly halted due to the
presumed combination of TGFβ-mediated growth inhibition
and DNA damage-associated cell cycle arrest after radiation.
These are primary targets for the therapeutic effect of Palif-
ermin, a potent growth factor. We found that the proliferative
effect of Smad7 in oral mucositis was not as pronounced as
that of Palifermin, but is sufﬁcient to restore proliferation to a
normal baseline level. Additionally, because Palifermin is
given systemically via i.v. injection, all keratinocytes in the
body go through hyperproliferation in response to Palifermin
treatment. In contrast, Tat-Smad7 can be administered
locally, avoiding stimulation of non-target cells, particularly
cancer cells away from the ulcer. Because Palifermin does
not fully protect cells from damage and apoptosis, hyper-
proliferation is needed to compensate for lost epithelial cells
to prevent oral mucositis. This could explain why Palifermin
needs to be administered three days before radiotherapy. In
contrast, a recent study has shown that Smad7 enhances
DNA repair after radiation by direct interactions with the ATM
DNA repair complex (Park et al., 2014). This effect, together
with its potent anti-inﬂammatory effect, could explain why
Tat-Smad7 treated oral mucosa has fewer damaged and
apoptotic cells than Palifermin-treated mucosa. Reduced
DNA damage and cell death would diminish the need for
hyperproliferation.
Role of Smad7 in acceleration of epithelial migration
When using Tat-Smad7 as a therapeutic agent for existing
oral mucositis, its role in epithelial migration would be
essential to initiate healing. During wound closure, re-epi-
thelialization relies primarily on rapid migration of keratino-
cytes at the wound edge and proliferation of the basal layer
of epithelial cells located adjacent to the wound site (Castilho
et al., 2010; Lawson and Burridge, 2014). We found that
knocking down Smad7 in normal human oral keratinocytes
abrogates cell migration (Han et al., 2013). This phenome-
non is strikingly comparable with loss of Rac1, a member of
the Rho family of GTPases necessary for oral wound healing
and keratinocyte migration (Liu et al., 2009; Castilho et al.,
2010). We found that Smad7 increases expression levels
and activities of Rac1 (Han et al., 2013). This ﬁnding was
initially surprising because TGFβ signaling is known to
activate Rac1 at the protein level via a Smad-independent
mechanism (Derynck and Zhang, 2003). Further analyses
revealed that Rac1 is repressed by Smad2/3/4, the protein
complex that recruits the transcriptional co-repressor CtBP1.
This Smad-mediated Rac1 repression is abrogated when
Smad7 prevents binding of Smad2/3/4 and CtBP1 to the
SBE site on the Rac1 promoter. Although it remains to be
determined if elevated TGFβ is able to activate Rac1 via a
non-Smad pathway in the context of oral mucositis, Smad-
dependent Rac1 repression could overcome Smad-inde-
pendent Rac1 activation. When this repression is nulliﬁed by
Smad7, Rac1-mediated epithelial migration and proliferation
are enabled. We also found much higher levels of endoge-
nous Rac1 in oral cancer cells than in normal keratinocytes.
In cancer cells, signaling Smads are lost or inactivated so
their repression of Rac1 would be absent or other oncogenic
mechanisms could independently activate Rac1. This
potentially explains why Smad7 preferentially activates Rac1
and promotes migration in normal, but not cancer, epithelial
cells.
SUMMARY AND PERSPECTIVES
Oral mucositis has multiple pathological processes, hence
targeting one of them is insufﬁcient for therapeutic efﬁcacy.
We found that Smad7 has both prophylactic and therapeutic
effects on radiation-induced oral mucositis in mice. At the
pathological level, Smad7 targets multiple pathological pro-
cesses required for oral mucositis development, particularly
through its effects on proliferation, apoptosis, migration in
keratinocytes, and reducing inﬂammation in the stroma. At
the molecular level, Smad7 functions in both the cytoplasm
and nucleus to dampen TGFβ and NF-κB pathways and
regulates targets to encourage oral mucositis healing
(Fig. 2).
Considering the pleotropic effects of Smad7, future
challenges to using Smad7-based therapy will be to pro-
mote wound healing without blocking TGFβ-mediated
tumor-suppressive effects. In most cancer types, loss of
TGFβ-mediated tumor suppression occurs at the molecular
level for TGFβ signaling components or through other
oncogenic pathways that override TGFβ-induced tumor
suppressive effects. In these tumors, Smad7 may not be
able to affect cancer cell behavior but instead selectively
affect healthy mucosa. However, TGFβ signaling is often
activated in tumor stroma. Consequently, Smad7 provides
tumor suppressive effects through the inhibition of TGFβ-
and NF-κB- mediated tumor promotion in tumor stroma
(Azuma et al., 2005; Hong et al., 2007; DiVito et al., 2010).
The effect of Smad7 on the stroma is consistent with the
rationale for using TGFβ inhibitors to treat advanced met-
astatic cancers in clinical trials. Nevertheless, the dosage
and time course need to be carefully assessed to minimize
the risk of Smad7 treatment causing a resurgence of can-
cer cells.
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Figure 2. Summary of potential mechanisms of Smad7-mediated protection and healing of oral mucositis (from Han et al.,
Nature Medicine, 2013). (A) Radiation activates NF-κB, increases TGFβ1 and CtBP1. NF-κB and TGFβ1 induce inﬂammation.
TGFβ1 induces apoptosis, growth arrest, and activates Smads which recruit CtBP1 to the Rac1 promoter to repress Rac1
transcription, leading to blunted re-epithelialization. (B) Smad7 blocks NF-κB and TGFβ1-induced inﬂammation and blocks TGFβ1-
induced apoptosis and growth arrest. Smad7 activates Rac1 by either preventing TGFβ1-mediated Smad phosphorylation or
competing with signaling Smads/CtBP1 transcriptional repression complex in the Rac1 promoter. Increased Rac1 induced by Smad7
contributes to keratinocyte migration during re-epithelialization.
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oxygen species; TGFβ, transforming growth factor β; TNF-α, tumor-
necrosis factor-α.
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